Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dynavax Technologies Corporation (DVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
16.94-0.08 (-0.47%)
At close: 4:00PM EDT
16.94 0.00 (0.00%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.02
Open17.10
Bid16.96 x 2200
Ask17.10 x 3100
Day's Range16.54 - 17.22
52 Week Range3.58 - 20.96
Volume1,701,028
Avg. Volume4,670,964
Market Cap1.941B
Beta (5Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-0.78
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
  • Benzinga

    President And COO Of Dynavax Technologies Makes $310K Sale

    David Novack, President And COO at Dynavax Technologies (NASDAQ:DVAX), made a large insider sell on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Novack sold 17,000 shares of Dynavax Technologies at a price of $18.23. The total transaction amounted to $309,844. Following the transaction, Novack still owns 67,066 shares of Dynavax Technologies worth $1,182,373. Dynavax Technologies shares are trading

  • SmarterAnalyst

    Dynavax Partners with DOD to Develop Adjuvanted Plague Vaccine

    Dynavax Technologies Corporation (DVAX), a biopharmaceutical company, has inked a deal with the U.S. Department of Defense (DOD) for $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018. Following the announcement, shares of the company rose 1.7% on Monday. As per the terms of the agreement, a Phase 2 clinical trial will be conducted by Dynavax, combining its CpG 1018 adjuvant with the DOD’s rF1V vaccine. The Phase 2 trial is likely to commence i

  • PR Newswire

    Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense (DOD) today announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018®. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD's rF1V vaccine. The Company anticipates the P

Advertisement
Advertisement